<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(10)</volume><submitter>Gianibbi B</submitter><pubmed_abstract>&lt;b>Background/Objectives&lt;/b>: Malaria remains the most critical parasitic disease globally, responsible for over 600.000 deaths annually. In sub-Saharan Africa, co-infections of &lt;i>Plasmodium falciparum&lt;/i> with other pathogens, particularly &lt;i>Staphylococcus aureus&lt;/i>, are common in children with severe malaria. Therefore, the design of new compounds targeting both pathogens appears to be an urgent priority. &lt;b>Methods&lt;/b>: A small series of hybrid compounds was designed and synthesized by linking the pharmacophore of the antimalarial drug chloroquine with the phenothiazine core. These compounds were tested in vitro against a panel of microbial strains and further analyzed through in silico simulations to predict their physical-chemical properties. &lt;b>Results&lt;/b>: Compounds &lt;b>4b&lt;/b> and</pubmed_abstract><journal>Antibiotics (Basel, Switzerland)</journal><pagination>991</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12561106</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>STOP Strategy to Inhibit &amp;lt;i&amp;gt;P. falciparum&amp;lt;/i&amp;gt; and &amp;lt;i&amp;gt;S. aureus&amp;lt;/i&amp;gt; Growth: Molecular Mechanism Studies on Purposely Designed Hybrids.</pubmed_title><pmcid>PMC12561106</pmcid><pubmed_authors>Gentilomi GA</pubmed_authors><pubmed_authors>Bonvicini F</pubmed_authors><pubmed_authors>Gobbi S</pubmed_authors><pubmed_authors>Belluti F</pubmed_authors><pubmed_authors>Bisi A</pubmed_authors><pubmed_authors>Basilico N</pubmed_authors><pubmed_authors>Parapini S</pubmed_authors><pubmed_authors>Corina R</pubmed_authors><pubmed_authors>Gianibbi B</pubmed_authors><pubmed_authors>Spiga O</pubmed_authors></additional><is_claimable>false</is_claimable><name>STOP Strategy to Inhibit &amp;lt;i&amp;gt;P. falciparum&amp;lt;/i&amp;gt; and &amp;lt;i&amp;gt;S. aureus&amp;lt;/i&amp;gt; Growth: Molecular Mechanism Studies on Purposely Designed Hybrids.</name><description>&lt;b>Background/Objectives&lt;/b>: Malaria remains the most critical parasitic disease globally, responsible for over 600.000 deaths annually. In sub-Saharan Africa, co-infections of &lt;i>Plasmodium falciparum&lt;/i> with other pathogens, particularly &lt;i>Staphylococcus aureus&lt;/i>, are common in children with severe malaria. Therefore, the design of new compounds targeting both pathogens appears to be an urgent priority. &lt;b>Methods&lt;/b>: A small series of hybrid compounds was designed and synthesized by linking the pharmacophore of the antimalarial drug chloroquine with the phenothiazine core. These compounds were tested in vitro against a panel of microbial strains and further analyzed through in silico simulations to predict their physical-chemical properties. &lt;b>Results&lt;/b>: Compounds &lt;b>4b&lt;/b> and</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-05-15T03:18:24.856Z</modification><creation>2026-05-15T03:12:26.05Z</creation></dates><accession>S-EPMC12561106</accession><cross_references><pubmed>41148683</pubmed><doi>10.3390/antibiotics14100991</doi></cross_references></HashMap>